Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)

Tara I. Chang, David M. Reboussin, Glenn M. Chertow, Alfred K. Cheung, William Cushman, William J. Kostis, Gianfranco Parati, Dominic Raj, Erik Riessen, Brian Shapiro, George S. Stergiou, Raymond R. Townsend, Konstantinos Tsioufs, Paul K. Whelton, Jeffrey Whittle, Jackson T. Wright, Vasilios Papademetriou

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Studies of visit-to-visit offce blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mmHg) or standard (<140 mmHg) systolic BP targets. We defned OBPV as the coeffcient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no signifcant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95% confdence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confdence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on offce BP control rather than on OBPV unless defnitive benefts of reducing OBPV are shown in prospective trials.

Original languageEnglish (US)
Pages (from-to)751-758
Number of pages8
JournalHypertension
Volume70
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Blood Pressure
Sodium Chloride Symporter Inhibitors
Mortality
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Coronary Disease
Heart Failure
Smoking
Stroke

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial). / Chang, Tara I.; Reboussin, David M.; Chertow, Glenn M.; Cheung, Alfred K.; Cushman, William; Kostis, William J.; Parati, Gianfranco; Raj, Dominic; Riessen, Erik; Shapiro, Brian; Stergiou, George S.; Townsend, Raymond R.; Tsioufs, Konstantinos; Whelton, Paul K.; Whittle, Jeffrey; Wright, Jackson T.; Papademetriou, Vasilios.

In: Hypertension, Vol. 70, No. 4, 01.01.2017, p. 751-758.

Research output: Contribution to journalArticle

Chang, TI, Reboussin, DM, Chertow, GM, Cheung, AK, Cushman, W, Kostis, WJ, Parati, G, Raj, D, Riessen, E, Shapiro, B, Stergiou, GS, Townsend, RR, Tsioufs, K, Whelton, PK, Whittle, J, Wright, JT & Papademetriou, V 2017, 'Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)', Hypertension, vol. 70, no. 4, pp. 751-758. https://doi.org/10.1161/HYPERTENSIONAHA.117.09788
Chang, Tara I. ; Reboussin, David M. ; Chertow, Glenn M. ; Cheung, Alfred K. ; Cushman, William ; Kostis, William J. ; Parati, Gianfranco ; Raj, Dominic ; Riessen, Erik ; Shapiro, Brian ; Stergiou, George S. ; Townsend, Raymond R. ; Tsioufs, Konstantinos ; Whelton, Paul K. ; Whittle, Jeffrey ; Wright, Jackson T. ; Papademetriou, Vasilios. / Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial). In: Hypertension. 2017 ; Vol. 70, No. 4. pp. 751-758.
@article{73ffaab2cb904af0abb646926723cfff,
title = "Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)",
abstract = "Studies of visit-to-visit offce blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mmHg) or standard (<140 mmHg) systolic BP targets. We defned OBPV as the coeffcient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no signifcant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95{\%} confdence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confdence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on offce BP control rather than on OBPV unless defnitive benefts of reducing OBPV are shown in prospective trials.",
author = "Chang, {Tara I.} and Reboussin, {David M.} and Chertow, {Glenn M.} and Cheung, {Alfred K.} and William Cushman and Kostis, {William J.} and Gianfranco Parati and Dominic Raj and Erik Riessen and Brian Shapiro and Stergiou, {George S.} and Townsend, {Raymond R.} and Konstantinos Tsioufs and Whelton, {Paul K.} and Jeffrey Whittle and Wright, {Jackson T.} and Vasilios Papademetriou",
year = "2017",
month = "1",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.117.09788",
language = "English (US)",
volume = "70",
pages = "751--758",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Visit-to-visit offce blood pressure variability and cardiovascular outcomes in SPRINT (systolic blood pressure intervention trial)

AU - Chang, Tara I.

AU - Reboussin, David M.

AU - Chertow, Glenn M.

AU - Cheung, Alfred K.

AU - Cushman, William

AU - Kostis, William J.

AU - Parati, Gianfranco

AU - Raj, Dominic

AU - Riessen, Erik

AU - Shapiro, Brian

AU - Stergiou, George S.

AU - Townsend, Raymond R.

AU - Tsioufs, Konstantinos

AU - Whelton, Paul K.

AU - Whittle, Jeffrey

AU - Wright, Jackson T.

AU - Papademetriou, Vasilios

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Studies of visit-to-visit offce blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mmHg) or standard (<140 mmHg) systolic BP targets. We defned OBPV as the coeffcient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no signifcant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95% confdence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confdence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on offce BP control rather than on OBPV unless defnitive benefts of reducing OBPV are shown in prospective trials.

AB - Studies of visit-to-visit offce blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mmHg) or standard (<140 mmHg) systolic BP targets. We defned OBPV as the coeffcient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no signifcant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95% confdence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confdence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on offce BP control rather than on OBPV unless defnitive benefts of reducing OBPV are shown in prospective trials.

UR - http://www.scopus.com/inward/record.url?scp=85030610011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030610011&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.117.09788

DO - 10.1161/HYPERTENSIONAHA.117.09788

M3 - Article

VL - 70

SP - 751

EP - 758

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -